Compare Neurocrine Biosciences Inc (NBIX) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs United States Natural Gas Fund — how do they compare? Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B), while United States Natural Gas Fund trades at $11.05 (market cap $517.27M). The key difference: Neurocrine Biosciences Inc is far larger — about 27.8× United States Natural Gas Fund's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and United States Natural Gas Fund for 22 Days on average.
| NBIX | UNG | |
|---|---|---|
Market Cap | $14.36B | $517.27M |
Volume | 1,237,180 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $185.50 | $16.90 |
52-Week Low | $123.10 | $9.63 |
Typical Hold Time | 23 Days | 22 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
UNG trades at $11.10, up 0.63% with a bullish technical signal from moving averages. The fund shows strong profitability with $65.15M net income for 2024, though revenue remains at $0.00. Recent news highlights natural gas market volatility with record production levels and geopolitical tensions affecting energy prices. The fund maintains a solid balance sheet with $594.68M in current assets and minimal liabilities.
Investment outlook remains cautiously optimistic given bullish technical indicators and strong profitability metrics. Key risks include natural gas price volatility and geopolitical factors affecting energy markets. The absence of traditional valuation metrics requires careful monitoring of underlying commodity trends for informed positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
